DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 145 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,332 | +0.1% | 3,251 | +10.8% | 0.00% | – |
| Q2 2023 | $41,289 | -2.3% | 2,934 | +7.2% | 0.00% | – |
| Q1 2023 | $42,271 | -40.6% | 2,737 | -36.8% | 0.00% | – |
| Q4 2022 | $71,147 | +58.1% | 4,331 | +78.0% | 0.00% | – |
| Q3 2022 | $45,000 | +50.0% | 2,433 | +4.3% | 0.00% | – |
| Q2 2022 | $30,000 | +36.4% | 2,333 | 0.0% | 0.00% | – |
| Q1 2022 | $22,000 | 0.0% | 2,333 | +2.5% | 0.00% | – |
| Q4 2021 | $22,000 | -87.0% | 2,275 | -54.2% | 0.00% | – |
| Q3 2021 | $169,000 | +4.3% | 4,965 | +12.0% | 0.00% | – |
| Q2 2021 | $162,000 | +7.3% | 4,433 | +31.7% | 0.00% | – |
| Q1 2021 | $151,000 | +371.9% | 3,365 | +517.4% | 0.00% | – |
| Q4 2020 | $32,000 | +10.3% | 545 | 0.0% | 0.00% | – |
| Q3 2020 | $29,000 | +314.3% | 545 | +369.8% | 0.00% | – |
| Q2 2020 | $7,000 | -70.8% | 116 | -83.4% | 0.00% | – |
| Q1 2020 | $24,000 | – | 698 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $69,030,000 | 15.95% |
| SV Health Investors, LLC | 449,951 | $25,679,000 | 12.37% |
| Sunesis Advisors, LLC | 96,299 | $5,496,000 | 4.45% |
| Redmile Group, LLC | 4,437,968 | $253,275,000 | 3.07% |
| Consonance Capital Management LP | 484,671 | $27,660,000 | 2.58% |
| SECTORAL ASSET MANAGEMENT INC | 488,842 | $27,898,000 | 1.97% |
| Opaleye Management Inc. | 222,000 | $12,670,000 | 1.66% |
| Eversept Partners, LP | 246,240 | $14,052,917 | 1.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 38,620 | $2,204,000 | 1.28% |
| Avoro Capital Advisors LLC | 1,300,000 | $74,191,000 | 1.28% |